Mylan has been accused of underpaying Medicaid in rebates for EpiPens, and agreed to pay $465 million to the government to resolve such claims. » Read More
Property and casualty insurer Travelers reported a 22.8 percent fall in quarterly net profit due to weaker underwriting.
Aviva CFO, Tom Stoddard, talks about the broader impact that Brexit has on the insurance sector.
Is the full suite of products given to clients nearly enough when it comes to the insurance space? Aviva CFO, Tom Stoddard, weighs in with comment on technology and disruption.
The sign-ups would represent a modest increase in enrollment over 2016.
UnitedHealth's shares are up nearly 14 percent year to date, outperforming the health care sector.
Shopping around for better coverage can cut your monthly premiums and out-of-pocket expenses by hundreds of dollars next year.
Peter Garnry, head of equity strategy at Saxo Bank, suggests the European insurance industry as a contrarian bet for investors.
Canadian drugmaker Valeant Pharmaceuticals said Friday it will increase the list prices of products in some of its portfolios by 2 percent to 9 percent.
Daniel Schreiber, Lemonade CEO, discusses how his start-up company plans to disrupt traditional insurers through its peer-to-peer model organized around charities.
Federal health officials are looking to get more uninsured and younger adults to sign up for Obamacare.
Medicare ratings cuts at Humana may signal a higher bar for other Medicare insurers, an analyst says.
A new study finds the average woman will spend 70 percent of her benefit payouts on medical expenses.
Federal health officials and the drug company Mylan are refusing to explain why full rebates for EpiPen are being delayed.
Zocdoc wants to make "Unsick Days" common, so workers can get checkups during a paid day off without having to worry about repercussions.
CNBC's Morgan Brennan reports on the damage that Hurricane Matthew caused through Florida, Georgia and the Carolinas.
Mylan has been under fire for months over sky-high price hikes of anti-allergy EpiPen devices.
Get the best of CNBC in your inbox